2. Search Result
Search Result
Results for "

HCV entry inhibitor

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

3

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116767
    BLT-1
    10+ Cited Publications

    Block lipid transport-1

    		 HCV Metabolic Disease Inflammation/Immunology
    BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .
    BLT-1
  • HY-N0248
    Saikosaponin B2
    2 Publications Verification

    		 HCV P-glycoprotein Infection Cancer
    Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
    Saikosaponin B2
  • HY-P991200
    OM-7D3-B3

    		HCV Claudin Infection
    OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (Kd=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .
    OM-7D3-B3
  • HY-N7934
    Trachelogenin

    (-)-Trachelogenin

    		 HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-P10974
    La peptide

    		HCV Enterovirus Infection
    La peptide (LAP) is an internal ribosome entry site (IRES) inhibitor. La peptide efficiently enters cells, blocks binding of cellular transacting factors to viral IRES, followed by inhibiting IRES-mediated translation. La peptide can be used for RNA viruses research, such as hepatitis C (HCV) and poliovirus (PV) .
    La peptide
  • HY-144106
    HCV-IN-33

    		HCV Infection
    HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor .
    HCV-IN-33
  • HY-144107
    HCV-IN-34

    		HCV Infection
    HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC50 of 0.010 μM and a CC50 (half-maximal cytotoxic concentration) of 8.23 μM .
    HCV-IN-34
  • HY-144110
    HCV-IN-37

    		HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    HCV-IN-37
  • HY-144109
    HCV-IN-36

    		HCV Infection
    HCV-IN-36 (compound (S)-3h) is an orally active and potent HCV entry inhibitor. HCV-IN-36 shows excellent antiviral activity, with an EC50 of 0.016 μM and a CC50 (half-maximal cytotoxic concentration) of 8.78 μM .
    HCV-IN-36
  • HY-118932
    HCV-IN-45

    		HCV Infection
    HCV-IN-45 (Compound EI-1) is an inhibitor for hepatitis C virus (HCV), that inhibits 1a and 1b HCV pseudoparticles with EC50 of 0.134 and 0.027 μM. HCV-IN-45 inhibits 1a/2a and 1b/2a cell culture-adapted HCV (HCVcc), with EC50 of 0.024 and 0.012μM. HCV-IN-45 inhibits the entry of the virus into hepatocyte, and blocks the cell-cell spread .
    HCV-IN-45
  • HY-153837
    ISIS 14803

    		HCV Infection
    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
    ISIS 14803
  • HY-153837A
    ISIS 14803 sodium

    		HCV Infection
    ISIS 14803 sodium is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
    ISIS 14803 sodium
  • HY-N0248R
    Saikosaponin B2 (Standard)

    		Reference Standards P-glycoprotein HCV Infection Cancer
    Saikosaponin B2 (Standard) is the analytical standard of Saikosaponin B2. This product is intended for research and analytical applications. Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
    Saikosaponin B2 (Standard)
  • HY-182679
    L0909

    		HCV Infection
    L0909 is an HCV inhibitor with an EC50 of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection .
    L0909
  • HY-107176
    (E)-Hyzetimibe

    (E)-HS-25

    		 Drug Isomer HCV Acyltransferase Infection Metabolic Disease
    (E)-Hyzetimibe ((E)-HS-25) (Compound I-1Z) is the trans isomer of Hyzetimibe (HY-107176A), a cholesterol-lowering agent. (E)-Hyzetimibe has cholesterol acyltransferase (ACTA) inhibitory activity, but its cholesterol-lowering effect is relatively weak. (E)-Hyzetimibe can inhibit the entry of hepatitis C virus (HCV) into host cells, and it has a synergistic effect when used in combination with interferon-α. (E)-Hyzetimibe can be used for the study of HCV infection .
    (E)-Hyzetimibe

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: